Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2015

View Archived Issues

Chugai reviews domestic and international developments of fourth quarter 2014

Eisai profiles developments of third quarter of fiscal 2014

Pfizer profiles pipeline progress of fourth quarter 2014

Novel BRD4 inhibitors disclosed by Bayer Schering Pharma

Merck & Co. divulges novel IRAK-4 inhibitors

Astex patents novel inhibitors of discoidin domain receptors

Glenmark Pharmaceuticals discloses new RORgamma-t modulators

Novartis reports new E-NPP 2 inhibitors

Acorda reports data from phase I trial of remyelinating antibody in MS

FDA grants breakthrough therapy designation to LentiGlobin for beta-thalassemia major

DiaMedica to develop DM-199 for acute vascular diseases

Lpath submits IND application for Lpathomab in neuropathic pain

Amitiza mutual recognition procedure closes with recommendation for approval

Researchers identify potential biomarker of keloid tissue formation

Symphogen regains rights to Sym-004 and focuses on oncology

IncellDx's OncoBreast3Dx technology set for studies in detection of early-stage breast cancer

Endo completes acquisition of Auxilium Pharmaceuticals

BioMarin completes tender offer for Prosensa stock

Alnylam begins phase I/II trial of ALN-CC5 for complement-mediated diseases

Cis-urocanic acid eye drops found safe in phase I study

Phase II/III study of two Ebola vaccines initiated in Liberia

Parent Project Muscular Dystrophy awards grant to UCLA team to develop exon skipping boosters

Repros submits Androxal NDA

FDA approves Glyxambi for type 2 diabetes

Afrezza launched in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...